{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:24:09Z","timestamp":1793744649531,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-C&T-B-120"],"award-info":[{"award-number":["2022-I2M-C&T-B-120"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["CIFMS"],"award-info":[{"award-number":["CIFMS"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["PKU2023LCXQ008"],"award-info":[{"award-number":["PKU2023LCXQ008"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RZ2022-03"],"award-info":[{"award-number":["RZ2022-03"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDJP2022-03"],"award-info":[{"award-number":["RDJP2022-03"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDX2023-07"],"award-info":[{"award-number":["RDX2023-07"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RS2022-05"],"award-info":[{"award-number":["RS2022-05"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021RU002"],"award-info":[{"award-number":["2021RU002"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92259303"],"award-info":[{"award-number":["92259303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L252064"],"award-info":[{"award-number":["L252064"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L234002"],"award-info":[{"award-number":["L234002"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z240013"],"award-info":[{"award-number":["Z240013"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109562","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:34:19Z","timestamp":1786059259000},"page":"109562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Distinct spatial immune microenvironment features of different EGFR mutation subtypes in early-stage lung adenocarcinoma"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7724-2225","authenticated-orcid":false,"given":"Kongxu","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sida","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-3053","authenticated-orcid":false,"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-6153","authenticated-orcid":false,"given":"Kezhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-9446","authenticated-orcid":false,"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0010","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109562_b0015","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109562_b0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109562_b0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.lungcan.2026.109562_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102664","article-title":"The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer","volume":"122","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109562_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009165","article-title":"Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect","volume":"12","author":"Lu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109562_b0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-Mutated non-small cell lung cancer","author":"He","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.lungcan.2026.109562_b0045","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study","volume":"42","author":"Blakely","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109562_b0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol."},{"issue":"25","key":"10.1016\/j.lungcan.2026.109562_b0055","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109562_b0060","article-title":"Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE\/CTONG2104)","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109562_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-022-00301-8","article-title":"Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: a multicenter pooled analysis","volume":"6","author":"Zhang","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109562_b0075","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7948","key":"10.1016\/j.lungcan.2026.109562_b0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41586-022-05672-3","article-title":"Single-cell spatial landscapes of the lung tumour immune microenvironment","volume":"614","author":"Sorin","year":"2023","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109562_b0085","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","article-title":"Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer","volume":"14","author":"Enfield","year":"2024","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109562_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003534","article-title":"Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109562_b0095","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41388-020-01528-0","article-title":"Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations","volume":"40","author":"He","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2026.109562_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.889886","article-title":"Multiplex immunofluorescence and the digital image analysis workflow for evaluation of the tumor immune environment in translational research","volume":"12","author":"Rojas","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000523751","article-title":"Impact of region-of-interest size on immune profiling using multiplex immunofluorescence tyramide signal amplification for paraffin-embedded tumor tissues","volume":"90","author":"Sun","year":"2023","journal-title":"Pathobiology"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymeth.2014.08.016","article-title":"Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis","volume":"70","author":"Stack","year":"2014","journal-title":"Methods"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109562_b0115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.gendis.2020.04.001","article-title":"The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC","volume":"9","author":"Wang","year":"2022","journal-title":"Genes Dis."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2026.109562_b0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41379-021-00932-5","article-title":"Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer","volume":"35","author":"Sholl","year":"2022","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109562_b0130","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1111\/cas.16253","article-title":"A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer","volume":"115","author":"Zhang","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2026.109562_b0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2020.02.010","article-title":"PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy","volume":"142","author":"Chen","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","article-title":"Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109562_b0145","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109562_b0150","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.22.02509","article-title":"US food and drug administration approval summary: nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer","volume":"41","author":"Akinboro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109562_b0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109562_b0160","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.21037\/tlcr-2025-962","article-title":"Exploring perioperative treatment for non-small cell lung cancer patients harboring EGFR mutation: a real-world multicenter cohort study","volume":"14","author":"Zhou","year":"2025","journal-title":"Transl Lung Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109562_b0165","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2026.44.16_suppl.8509","article-title":"Neoadjuvant almonertinib followed by chemo-immunotherapy in II-IIIb EGFR-mutant NSCLC: a single arm, phase II study (NEOVADE)","volume":"44","author":"Lin","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109562_b0170","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1860586","article-title":"A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma","volume":"10","author":"Budczies","year":"2021","journal-title":"Oncoimmunology"},{"issue":"7791","key":"10.1016\/j.lungcan.2026.109562_b0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"7791","key":"10.1016\/j.lungcan.2026.109562_b0180","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"issue":"7791","key":"10.1016\/j.lungcan.2026.109562_b0185","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2026.109562_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102990","article-title":"Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"60","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109562_b0195","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109562_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.602328","article-title":"Prognostic biomarker TP53 mutations for immune checkpoint blockade therapy and its association with tumor microenvironment of lung adenocarcinoma","volume":"7","author":"Lin","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109562_b0205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2023.12.015","article-title":"Outcome of first-line treatment with pembrolizumab according to KRAS\/TP53 mutational status for nonsquamous programmed death-ligand 1-High (\u226550%) NSCLC in the German national network genomic medicine lung cancer","volume":"19","author":"Bischoff","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109562_b0210","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/gutjnl-2021-324339","article-title":"Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny","volume":"71","author":"Sheng","year":"2022","journal-title":"Gut"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:53:56Z","timestamp":1789145636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0169500226006239"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109562","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct spatial immune microenvironment features of different EGFR mutation subtypes in early-stage lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109562"}}